| scholarly article | Q13442814 |
| P356 | DOI | 10.1023/A:1012244520615 |
| P698 | PubMed publication ID | 11697464 |
| P50 | author | Tsutomu Nakamura | Q57023886 |
| P2093 | author name string | K Okumura | |
| M Hirai | |||
| M Kasuga | |||
| T Tamura | |||
| T Sakai | |||
| M Kakumoto | |||
| Y Morita | |||
| N Aoyama | |||
| T Sakaeda | |||
| M Horinouchi | |||
| N Ohmoto | |||
| P2860 | cites work | Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues | Q24633406 |
| Recent progress in P-glycoprotein research. | Q33686903 | ||
| Multidrug resistance in human tumors--molecular diagnosis and clinical significance | Q33720478 | ||
| Role of P-glycoprotein in drug disposition | Q33845762 | ||
| Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs | Q34059522 | ||
| The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. | Q34162850 | ||
| A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants | Q34488592 | ||
| Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine | Q34620070 | ||
| Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo | Q35113118 | ||
| Clinical pharmacokinetic significance of the renal tubular secretion of digoxin | Q39684941 | ||
| Purification of genomic DNA from human whole blood by isopropanol-fractionation with concentrated Nal and SDS. | Q40399731 | ||
| Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals | Q40624014 | ||
| The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin | Q40851439 | ||
| Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone | Q41590183 | ||
| Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). | Q41596609 | ||
| Isolation of DNA from biological specimens without extraction with phenol | Q70044147 | ||
| Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum) | Q73145709 | ||
| The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs | Q77182829 | ||
| P433 | issue | 10 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 1400-1404 | |
| P577 | publication date | 2001-10-01 | |
| P1433 | published in | Pharmaceutical Research | Q7180737 |
| P1476 | title | MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects | |
| P478 | volume | 18 |
| Q44635593 | ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation |
| Q48824586 | ABCB1 C3435T polymorphism influences the risk for Alzheimer's disease. |
| Q92219623 | ABCB1 Polymorphisms and Drug-Resistant Epilepsy in a Tunisian Population |
| Q36592129 | ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. |
| Q39145949 | An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure |
| Q50522192 | Association Between Tacrolimus Pharmacokinetics and Cytochrome P450 3A5 and Multidrug Resistance Protein 1 Exon 21 Polymorphisms. |
| Q48158334 | Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese |
| Q54014856 | Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. |
| Q36353785 | Blood-brain barrier P-glycoprotein function in healthy subjects and Alzheimer's disease patients: effect of polymorphisms in the ABCB1 gene |
| Q38431150 | Clinical association between pharmacogenomics and adverse drug reactions |
| Q97905256 | Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin |
| Q41987346 | Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction: MDR1 single nucleotide polymorphism genotyping assay |
| Q79175494 | Detection of the four sequence variations of MDR1 gene using TaqMan® MGB probe based real-time PCR and haplotype analysis in healthy Japanese subjects |
| Q86525182 | Different frequencies and effects of ABCB1 T3435C polymorphism on clinical and laboratory features of B cell chronic lymphocytic leukemia in Kurdish patients |
| Q57314091 | Digoxin pharmacokinetics and MDR1 genetic polymorphisms |
| Q28069761 | Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter? |
| Q41123798 | Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects |
| Q43055993 | Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren |
| Q34099716 | Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. |
| Q46307844 | Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem |
| Q43281164 | Effect of the ABCB1 3435C>T polymorphism on tacrolimus concentrations and dosage requirements in liver transplant recipients. |
| Q37100443 | Effect of the C3435T polymorphism of the multidrug resistance 1 gene on the severity of inflammatory bowel disease in Iranian Azeri Turks. |
| Q64987306 | Effects of ABCB1 gene polymorphisms on autonomic nervous system activity during atypical antipsychotic treatment in schizophrenia. |
| Q54377892 | Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. |
| Q36597641 | Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics |
| Q37705351 | Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation |
| Q44854113 | Functional analysis of genetic variations in the 5'-flanking region of the human MDR1 gene |
| Q35814113 | Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). |
| Q36410400 | Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer |
| Q37491021 | Genetic polymorphisms of enzyme proteins and transporters related to methotrexate response and pharmacokinetics in a Japanese population |
| Q35941387 | Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives |
| Q47572599 | Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy |
| Q87424305 | Genetic variability and haplotype profile of MDR1 in Saudi Arabian males |
| Q46891918 | Genotype and allele frequency of human multidrug resistance (MDR1) gene C3435T polymorphism in Denizli province of Turkey |
| Q73466818 | Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities |
| Q35070838 | Human pharmacogenomic variations and their implications for antifungal efficacy |
| Q38414396 | Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature |
| Q35575700 | Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution |
| Q35102211 | Implications of pharmacogenetics for individualizing drug treatment and for study design |
| Q58766132 | Improvement of Adequate Digoxin Dosage: An Application of Machine Learning Approach |
| Q33660159 | Incidence of genetic polymorphisms involved in lipid metabolism among Chinese patients with osteonecrosis of the femoral head |
| Q48218900 | Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study |
| Q43244739 | Influence of ABCB1 gene polymorphisms on the pharmacokinetics of azithromycin among healthy Chinese Han ethnic subjects |
| Q42246055 | Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects |
| Q38307360 | Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies |
| Q84212544 | Influence of MDR1 polymorphism on H. pylori-related chronic gastritis |
| Q35153169 | Intestinal drug absorption and bioavailability: beyond involvement of single transport function |
| Q28533307 | Linkage disequilibrium between polymorphisms of ABCB1 and ABCC2 to predict the treatment outcome of Malaysians with complex partial seizures on treatment with carbamazepine mono-therapy at the Kuala Lumpur Hospital |
| Q45179972 | Linking pharmacovigilance with pharmacogenetics |
| Q39204093 | Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters |
| Q36417994 | MDR1 gene polymorphisms and clinical relevance |
| Q73375325 | MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects |
| Q35804210 | MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males |
| Q35071734 | Meta-Analysis of ABCB1 3435C>T Polymorphism and Colorectal Cancer |
| Q35827187 | Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression |
| Q34538009 | Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis |
| Q36762177 | Multifactorial etiology of gastric cancer |
| Q47949113 | P-glycoprotein function in the elderly |
| Q83984019 | Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population |
| Q36478845 | Pharmacogenetics approach to therapeutics |
| Q26852239 | Pharmacogenetics in chronic heart failure: new developments and current challenges |
| Q35164664 | Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs |
| Q38242601 | Pharmacogenetics of membrane transporters: a review of current approaches. |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q27692687 | Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine |
| Q35562024 | Pharmacogenomics of immunosuppressive drug metabolism |
| Q35090217 | Pharmacogenomics: marshalling the human genome to individualise drug therapy |
| Q58800138 | Polymorphism C3435T of the MDR1 gene in Central Americans and Spaniards |
| Q42703883 | Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study |
| Q90585734 | Population Pharmacokinetic and Exposure-Response Analyses of Baloxavir Marboxil in Adults and Adolescents Including Patients With Influenza |
| Q37729221 | Population pharmacokinetic model of digoxin in older Chinese patients and its application in clinical practice |
| Q47822510 | Population pharmacokinetics of gabapentin in healthy Korean subjects with influence of genetic polymorphisms of ABCB1. |
| Q38684291 | Possibility of Predicting Serotonin Transporter Occupancy From the In Vitro Inhibition Constant for Serotonin Transporter, the Clinically Relevant Plasma Concentration of Unbound Drugs, and Their Profiles for Substrates of Transporters |
| Q42751321 | Post-mortem ABCB1 genotyping reveals an elevated toxicity for female digoxin users |
| Q80259910 | Prediction of systemic exposure to cyclosporine in Japanese pediatric patients |
| Q46441772 | Relationship between loperamide-induced sedative effect and digoxin pharmacokinetics in healthy Japanese subjects |
| Q34400733 | Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver |
| Q35029495 | Role of P-glycoprotein in pharmacokinetics: clinical implications |
| Q78498308 | Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin |
| Q60678552 | Simultaneous screening for three mutations in the ABCB1 gene |
| Q46681441 | Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in a West Black African population |
| Q36456067 | Steroid biosynthesis and renal excretion in human essential hypertension: association with blood pressure and endogenous ouabain. |
| Q58869670 | The Effect of CYP3A5 and MDR1 Polymorphic Expression on Cyclosporine Oral Disposition in Renal Transplant Patients |
| Q35817004 | The MDR1 (ABCB1) gene polymorphism and its clinical implications |
| Q35191432 | The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. |
| Q35793721 | The complexities of hepatic drug transport: current knowledge and emerging concepts. |
| Q41693100 | The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome |
| Q34156828 | The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans |
| Q33714593 | Xenobiotic, bile acid, and cholesterol transporters: function and regulation. |
| Q44568322 | pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. |
Search more.